139 related articles for article (PubMed ID: 37811569)
1. Impact of
Ramakrishnan K; Kesavan R; Venkatraman S; Narayan SK; Kumar RR; Shewade D
Per Med; 2023 Sep; 20(5):417-424. PubMed ID: 37811569
[TBL] [Abstract][Full Text] [Related]
2. Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy.
Wang C; Wang P; Yang LP; Pan J; Yang X; Ma HY
Epilepsy Res; 2017 May; 132():64-69. PubMed ID: 28315807
[TBL] [Abstract][Full Text] [Related]
3. Relevance of CYP2C9 Function in Valproate Therapy.
Monostory K; Nagy A; Tóth K; Bűdi T; Kiss Á; Déri M; Csukly G
Curr Neuropharmacol; 2019; 17(1):99-106. PubMed ID: 29119932
[TBL] [Abstract][Full Text] [Related]
4. Impact of CYP2C19 and CYP2C9 gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy.
Song C; Li X; Mao P; Song W; Liu L; Zhang Y
Eur J Hosp Pharm; 2022 Jul; 29(4):198-201. PubMed ID: 32868386
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of CYP2C9-status guided valproic acid therapy in children.
Bűdi T; Tóth K; Nagy A; Szever Z; Kiss Á; Temesvári M; Háfra E; Garami M; Tapodi A; Monostory K
Epilepsia; 2015 Jun; 56(6):849-55. PubMed ID: 25967074
[TBL] [Abstract][Full Text] [Related]
6. Associations of CYP2C9 and CYP2A6 Polymorphisms with the Concentrations of Valproate and its Hepatotoxin Metabolites and Valproate-Induced Hepatotoxicity.
Zhao M; Zhang T; Li G; Qiu F; Sun Y; Zhao L
Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):138-143. PubMed ID: 28273397
[TBL] [Abstract][Full Text] [Related]
7. Effects of
Zheng XX; You YX; Zhao LL; Du Y; Xu SQ; Tang DQ
Pharmacogenomics; 2023 Feb; 24(3):153-162. PubMed ID: 36718958
[No Abstract] [Full Text] [Related]
8. Early post-traumatic seizures are associated with valproic acid plasma concentrations and UGT1A6/CYP2C9 genetic polymorphisms in patients with severe traumatic brain injury.
Sun Y; Yu J; Yuan Q; Wu X; Wu X; Hu J
Scand J Trauma Resusc Emerg Med; 2017 Aug; 25(1):85. PubMed ID: 28841884
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients.
Gunes A; Bilir E; Zengil H; Babaoglu MO; Bozkurt A; Yasar U
Basic Clin Pharmacol Toxicol; 2007 Jun; 100(6):383-6. PubMed ID: 17516991
[TBL] [Abstract][Full Text] [Related]
10. Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy.
Chaudhary N; Kabra M; Gulati S; Gupta YK; Pandey RM; Bhatia BD
BMC Pediatr; 2016 May; 16():66. PubMed ID: 27179628
[TBL] [Abstract][Full Text] [Related]
11. Influence of CYP2C9 and CYP2A6 on plasma concentrations of valproic acid: a meta-analysis.
Yoon HY; Ahn MH; Yee J; Lee N; Han JM; Gwak HS
Eur J Clin Pharmacol; 2020 Aug; 76(8):1053-1058. PubMed ID: 32385545
[TBL] [Abstract][Full Text] [Related]
12. CYP2C9 (*2&*3) and CYP2C19 (*2&*3) polymorphisms among children with nonlesional epilepsy: a single-center study.
Eltalal S; El Ayouty M; El-Said A; Wahba Y
Acta Neurol Belg; 2021 Dec; 121(6):1623-1631. PubMed ID: 32683556
[TBL] [Abstract][Full Text] [Related]
13. Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy.
Zhu X; Li X; Zhang T; Zhao L
Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):628-634. PubMed ID: 29791065
[TBL] [Abstract][Full Text] [Related]
14. Association of CYP2C9 polymorphisms with phenytoin toxicity in Indian patients.
Thakkar AN; Bendkhale SR; Taur SR; Gogtay NJ; Thatte UM
Neurol India; 2012; 60(6):577-80. PubMed ID: 23287317
[TBL] [Abstract][Full Text] [Related]
15. CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.
Franco V; Perucca E
Expert Opin Drug Metab Toxicol; 2015; 11(8):1269-79. PubMed ID: 26037375
[TBL] [Abstract][Full Text] [Related]
16. Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy.
Guo Y; Hu C; He X; Qiu F; Zhao L
Drug Metab Pharmacokinet; 2012; 27(5):536-42. PubMed ID: 23099353
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of UGT1A6 polymorphisms in children with epilepsy on valproate monotherapy.
Jain P; Shastri S; Gulati S; Kaleekal T; Kabra M; Gupta N; Gupta YK; Pandey RM
Neurol India; 2015; 63(1):35-9. PubMed ID: 25751467
[TBL] [Abstract][Full Text] [Related]
18. CYP2C9 and ABCG2 polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: a case-control study.
Miroševic Skvrce N; Božina N; Zibar L; Barišic I; Pejnovic L; Macolic Šarinic V
Pharmacogenomics; 2013 Sep; 14(12):1419-31. PubMed ID: 24024895
[TBL] [Abstract][Full Text] [Related]
19. Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data.
Smith RL; Haslemo T; Refsum H; Molden E
Eur J Clin Pharmacol; 2016 Sep; 72(9):1099-104. PubMed ID: 27353638
[TBL] [Abstract][Full Text] [Related]
20. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients.
Tan L; Yu JT; Sun YP; Ou JR; Song JH; Yu Y
Clin Neurol Neurosurg; 2010 May; 112(4):320-3. PubMed ID: 20089352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
